

## 14. その他必要な事項

### (1) 文献

1. 小柳知彦、村井 勝、大島伸一(編):新 図説泌尿器科学講座3 泌尿器科腫瘍学. メジカルビュー社、東京、76-95、1999
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. *N Engl J Med* 353, 2477-90,2005.
3. Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). *J Clin Oncol* 23, 4172-78,2005
4. Jonasch E and Haluska FG: Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. *Oncologist* 6, 34-55, 2001
5. Rinehart JJ, Young D, Laforge J, Colborn D, Neidhart JA : Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects. *Cancer Res* 47, 2481-2485, 1987
6. 新島端夫 : インターフェロン- $\beta$  (MR21)の腎細胞癌および膀胱癌に対する臨床効果の検討. *Journal of Japan Society Cancer Therapy* 22, 928-933, 1987
7. 水谷陽一、三木恒治 : エビデンスに基づいたバイオセラピーの有用性“インターフェロン”. *Biotherapy* 16、49-52、2002
8. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urban WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. *J Clin Oncol.* 23, 133-141,2005
9. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA : Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. *J Clin Oncol.* 21, 3127-32, 2003
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med.* 356, 115-24, 2007
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group.: Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med.* 356, 125-34, 2007
12. Childs R, Cheronoff A, Contentin N, Bahceci E, Schrupp D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ : Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med* 343, 750-758, 2000
13. Uemura H, Fujimoto K, Tanaka M, Yoshikawa M, Hirao Y, Uejima S, Yoshikawa K, Itoh K. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. *Clin Cancer Res* 12, 1768-75,2006
14. Mizuno M, Yoshida J, Sugita K, Inoue I, Seo H, Hayashi Y, Koshizaka T, Yagi K : Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody. *Cancer Res* 50, 7826-7829, 1990
15. Yoshida J, Mizuno M, Yagi K : Cytotoxicity of human  $\beta$ -interferon produced by human glioma cells transfected with its gene by means of liposomes. *Biochem Int* 28, 1055-1061, 1992
16. Yagi K, Noda H, Kurono M, Ohishi N : Efficient gene transfer with less cytotoxicity by means of cationic multilamellar liposomes. *Biochem Biophys Res Commun* 196, 1042-1048, 1993
17. Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferon- $\beta$  gene transfer against intracerebral glioma in mouse. *Gene Ther* 6, 1626-1633, 1999
18. Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J : IFN- $\beta$  gene therapy induces systemic